You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
尖峯集團(600668.SH):鹽酸奧洛他定滴眼液獲得藥品補充申請批准通知書
格隆匯 08-13 16:32

格隆匯8月13日丨尖峯集團(600668.SH)公佈,全資子公司浙江尖峯藥業有限公司收到國家藥品監督管理局核准簽發的鹽酸奧洛他定滴眼液《藥品補充申請批准通知書》,鹽酸奧洛他定是第三代強效安全的抗過敏藥,由日本協和發酵公司開發,於1997年和2001年分別在美國和日本上市。比利時愛爾康公司將其開發成0.1%滴眼液,商品名為Patanol(帕坦洛),用於治療過敏性結膜炎。鹽酸奧洛他定具有抑制組胺釋放及選擇性拮抗H1受體的雙重作用,且無H1受體拮抗劑類過敏藥常見的中樞神經系統抑制及心臟毒副作用,臨牀多用於治療過敏性鼻炎、蕁麻疹、皮炎等,是新一代的抗過敏首選藥,是肥大細胞穩定劑及相對選擇性組胺H1-受體拮抗劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account